Studybox Research 510(k) Clinical Studies

Drugs of Abuse Urine Screening Panel

Clinical and analytical performance to support substantial equivalence.

Studybox

510(k) Clinical Studies

Urine drug screening cups and dip cards are qualitative immunoassays, and their clinical study is organized around the cutoff for each analyte. The accepted design tests clinical specimens whose confirmed concentrations fall well below, just below, just above and well above each cutoff, so that the device's behavior in the uncertain zone near the cutoff is characterized rather than hidden in overall agreement. Every clinical specimen is confirmed by mass spectrometry, not just the discordant ones.

Panels with many analytes multiply the work: each drug class needs its own set of positives across the concentration strata, and low-prevalence drugs in a given population (barbiturates, PCP, methadone) are rarely found in sufficient numbers prospectively and are typically supplemented with characterized or spiked specimens, reported as such. Cross-reactivity with structurally related prescription and over-the-counter medications is a parallel analytical program whose results shape the labeling.

Analyte: Multiple drug classes and metabolites at defined cutoff concentrations (commonly amphetamines, methamphetamine, cocaine metabolite, opiates, oxycodone, THC metabolite, benzodiazepines, barbiturates, methadone, buprenorphine and PCP, depending on the panel)
Therapeutic area: Drugs of Abuse
Specimens: Urine
Intended-use settings: physician office, urgent care, home use, emergency department
Operators: Non-laboratory staff in physician offices, urgent care, treatment programs and workplace collection sites with waived certificates; lay users for over-the-counter versions.
Comparator: Typically confirmatory liquid chromatography-tandem mass spectrometry (LC-MS/MS) or GC-MS quantitation of the target analyte(s) for each drug class, with results classified relative to the device cutoff.

510(k) Studies specifics

What Changes for This Assay on This Pathway.

Each analyte is treated as its own device for performance purposes, with agreement reported by concentration stratum relative to the cutoff and with the confirmatory target analyte and cutoff stated in labeling.
Spiked and characterized specimens used to fill near-cutoff and low-prevalence strata are typically reported separately from unaltered clinical specimens.
Cross-reactivity and interference data, including common adulterants and specimen validity parameters, are expected for each analyte and are a frequent source of labeling limitations.

Endpoints the study must support

Percent agreement with the confirmatory method for each analyte, stratified by concentration relative to the cutoff (negative, near-cutoff negative, near-cutoff positive, high positive)
Precision near the cutoff for each analyte, typically using specimens at defined fractions above and below the cutoff
Untrained operator and, for over-the-counter claims, lay user agreement and interpretation of multi-strip results

Enrollment realities

Driven by near-cutoff and low-prevalence analyte positives, which rarely occur in sufficient numbers prospectively; studies typically combine prospective collection at treatment and clinical sites with characterized specimens. Specimen count per analyte per stratum matters more than subject count.

How Studybox runs it

Pre-Qualified Sites, Embedded Coordinators.

Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →

Same assay, other pathways

Relevant FDA guidance

FAQ

Drugs of Abuse Urine Screening Panel Study Questions.

01 Who operates the drugs of abuse urine screening panel in a 510(k) studies study?

Non-laboratory staff in physician offices, urgent care, treatment programs and workplace collection sites with waived certificates; lay users for over-the-counter versions.

02 What is the comparator for a drugs of abuse urine screening panel study?

Typically confirmatory liquid chromatography-tandem mass spectrometry (LC-MS/MS) or GC-MS quantitation of the target analyte(s) for each drug class, with results classified relative to the device cutoff.

03 What drives enrollment for a drugs of abuse urine screening panel study?

Let's talk IVD research

Planning a drugs of abuse urine screening panel study?

Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.